JP2000510124A5 - - Google Patents

Download PDF

Info

Publication number
JP2000510124A5
JP2000510124A5 JP1997540211A JP54021197A JP2000510124A5 JP 2000510124 A5 JP2000510124 A5 JP 2000510124A5 JP 1997540211 A JP1997540211 A JP 1997540211A JP 54021197 A JP54021197 A JP 54021197A JP 2000510124 A5 JP2000510124 A5 JP 2000510124A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP1997540211A
Other languages
English (en)
Japanese (ja)
Other versions
JP2000510124A (ja
JP4766722B2 (ja
Filing date
Publication date
Priority claimed from US08/643,321 external-priority patent/US6498142B1/en
Application filed filed Critical
Publication of JP2000510124A publication Critical patent/JP2000510124A/ja
Publication of JP2000510124A5 publication Critical patent/JP2000510124A5/ja
Application granted granted Critical
Publication of JP4766722B2 publication Critical patent/JP4766722B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP54021197A 1996-05-06 1997-05-06 慢性腎不全の形態形成因子処置 Expired - Fee Related JP4766722B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/643,321 1996-05-06
US08/643,321 US6498142B1 (en) 1996-05-06 1996-05-06 Morphogen treatment for chronic renal failure
PCT/US1997/007816 WO1997041881A1 (en) 1996-05-06 1997-05-06 Morphogen treatment for chronic renal failure

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2009126963A Division JP5247593B2 (ja) 1996-05-06 2009-05-26 慢性腎不全の形態形成因子処置

Publications (3)

Publication Number Publication Date
JP2000510124A JP2000510124A (ja) 2000-08-08
JP2000510124A5 true JP2000510124A5 (cg-RX-API-DMAC10.html) 2005-01-13
JP4766722B2 JP4766722B2 (ja) 2011-09-07

Family

ID=24580305

Family Applications (4)

Application Number Title Priority Date Filing Date
JP09540150A Pending JP2000510835A (ja) 1996-05-06 1997-05-06 慢性腎不全の治療
JP54021197A Expired - Fee Related JP4766722B2 (ja) 1996-05-06 1997-05-06 慢性腎不全の形態形成因子処置
JP2009126963A Expired - Fee Related JP5247593B2 (ja) 1996-05-06 2009-05-26 慢性腎不全の形態形成因子処置
JP2012179876A Withdrawn JP2012229268A (ja) 1996-05-06 2012-08-14 慢性腎不全の形態形成因子処置

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP09540150A Pending JP2000510835A (ja) 1996-05-06 1997-05-06 慢性腎不全の治療

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2009126963A Expired - Fee Related JP5247593B2 (ja) 1996-05-06 2009-05-26 慢性腎不全の形態形成因子処置
JP2012179876A Withdrawn JP2012229268A (ja) 1996-05-06 2012-08-14 慢性腎不全の形態形成因子処置

Country Status (11)

Country Link
US (5) US6498142B1 (cg-RX-API-DMAC10.html)
EP (2) EP0910400B1 (cg-RX-API-DMAC10.html)
JP (4) JP2000510835A (cg-RX-API-DMAC10.html)
AT (2) ATE245997T1 (cg-RX-API-DMAC10.html)
AU (2) AU2933997A (cg-RX-API-DMAC10.html)
CA (2) CA2254953C (cg-RX-API-DMAC10.html)
DE (2) DE69730966T2 (cg-RX-API-DMAC10.html)
DK (2) DK0910400T3 (cg-RX-API-DMAC10.html)
ES (2) ES2203803T3 (cg-RX-API-DMAC10.html)
PT (2) PT910400E (cg-RX-API-DMAC10.html)
WO (2) WO1997041881A1 (cg-RX-API-DMAC10.html)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6077823A (en) * 1991-03-11 2000-06-20 Creative Biomolecules, Inc. Method for reducing tissue damage associated with ischemia-reperfusion or hypoxia injury
CA2104678C (en) * 1991-03-11 2002-05-14 Charles M. Cohen Protein-induced morphogenesis
US20030167492A1 (en) 1994-07-08 2003-09-04 Johns Hopkins University School Of Medicine Transgenic non-human animals expressing a gdf-11 dominant negative polypeptide, and methods of making and using same
US6498142B1 (en) * 1996-05-06 2002-12-24 Curis, Inc. Morphogen treatment for chronic renal failure
JP5033276B2 (ja) * 1997-05-05 2012-09-26 ストライカー コーポレイション 急性腎不全の治療
WO1998050061A1 (en) * 1997-05-07 1998-11-12 Biogen, Inc. Novel therapies for cystic kidney disease
ATE220564T1 (de) 1997-08-14 2002-08-15 Sulzer Innotec Ag Zusammensetzung und vorrichtung zur reparatur von knorpelgewebe in vivo bestehend aus nanokapseln mit osteoinduktiven und/oder chondroinduktiven faktoren
US6203788B1 (en) * 1997-09-29 2001-03-20 Adherex Inc. Compounds and methods for regulating cell adhesion
CA2314423A1 (en) * 1997-12-04 1999-06-10 Creative Biomolecules, Inc. Maintenance of smooth muscle integrity by morphogenic proteins
NZ509609A (en) * 1998-07-28 2003-11-28 Univ Johns Hopkins Med Disrupting growth differentiation factor-11 (GDF-11) to increase the muscle and bone tissue in animals
US7087577B2 (en) * 1998-10-16 2006-08-08 Zimmer Orthobiologies, Inc. Method of promoting natural bypass
US6992066B2 (en) 1998-10-16 2006-01-31 Zimmer Orthobiologics, Inc. Povidone-containing carriers for polypeptide growth factors
JP4975922B2 (ja) * 1999-09-14 2012-07-11 バイオジェン・アイデック・エムエイ・インコーポレイテッド 1つ以上のインテグリンアンタゴニストを使用する慢性腎不全の治療
US20020173453A1 (en) * 2000-12-15 2002-11-21 Rama Akella Method of treating renal injury
US7700819B2 (en) 2001-02-16 2010-04-20 Kci Licensing, Inc. Biocompatible wound dressing
US7763769B2 (en) 2001-02-16 2010-07-27 Kci Licensing, Inc. Biocompatible wound dressing
US7232802B2 (en) 2001-12-21 2007-06-19 Zimmer Orthobiologics, Inc. Compositions and methods for promoting myocardial and peripheral angiogenesis
US7622562B2 (en) 2002-06-26 2009-11-24 Zimmer Orthobiologics, Inc. Rapid isolation of osteoinductive protein mixtures from mammalian bone tissue
WO2004019876A2 (en) * 2002-08-28 2004-03-11 Curis, Inc. Conjoint administration of morphogens and ace inhibitors in treatment of chronic renal failure
EP1677735B1 (en) 2003-10-17 2014-07-23 Joslin Diabetes Center, Inc. Methods and compositions for modulating adipocyte function
US7844367B2 (en) 2003-12-23 2010-11-30 Rain Bird Corporation Code replacement for irrigation controllers
MXPA06011270A (es) 2004-03-30 2007-03-08 Ilypsa Inc Composiciones fijadoras de iones.
JP2008500816A (ja) * 2004-03-31 2008-01-17 ゼンコー・インコーポレイテッド 改善された性質を有するbmp−7変異体
WO2006130690A2 (en) 2005-06-01 2006-12-07 Joslin Diabetes Center, Inc. Methods and compositions for inducing brown adipogenesis
US7771995B2 (en) * 2005-11-14 2010-08-10 Merial Limited Plasmid encoding human BMP-7
EP1951751B1 (en) 2005-11-14 2017-11-01 Merial, Inc. Gene therapy for renal failure
US20090004159A1 (en) * 2006-01-24 2009-01-01 The Board Of Trustees Of The University Of Illinoi Polymerized Hemoglobin Media and Its Use in Isolation and Transplantation of Islet Cells
US20070196810A1 (en) * 2006-01-24 2007-08-23 Northfield Laboratories Inc. Polymerized Hemoglobin Media and its Use in Isolation and Transplantation of Islet Cells
US20080090765A1 (en) * 2006-05-25 2008-04-17 The Trustees Of Columbia University In The City Of New York Compositions for modulating growth of embryonic and adult kidney tissue and uses for treating kidney damage
EP2035835B1 (en) 2006-05-30 2011-12-28 Antibodyshop A/S Methods for rapid assessment of severity of a trauma
US7722665B2 (en) 2006-07-07 2010-05-25 Graft Technologies, Inc. System and method for providing a graft in a vascular environment
EP2047862B9 (en) * 2006-07-21 2013-04-10 Chugai Seiyaku Kabushiki Kaisha Remedy for renal disease
EP2114390A2 (en) * 2006-12-15 2009-11-11 Ruprecht-Karls-Universität Heidelberg Methods for treating podocyte-related disorders
AU2008245900B2 (en) * 2007-04-24 2013-07-25 Advanced Technologies And Regenerative Medicine, Llc Engineered renal tissue
DE102007034580B4 (de) * 2007-07-13 2012-11-08 NMI Naturwissenschaftliches und Medizinisches Institut an der Universität Tübingen Biomaterial basierend auf einem hydrophilen polymeren Träger
US20090155245A1 (en) * 2007-12-18 2009-06-18 Fang Carrie H Treatment for Organ Regeneration with Combination of Drug and Biologics
CA2725208A1 (en) * 2008-05-06 2009-11-12 Joslin Diabetes Center, Inc. Methods and compositions for inducing brown adipogenesis
WO2009157165A1 (ja) * 2008-06-24 2009-12-30 株式会社根本杏林堂 薬液注入装置、この薬液注入装置を有する透視撮像システム、薬液注入装置のコンピュータプログラムおよびデータ処理方法
WO2010025424A1 (en) * 2008-08-28 2010-03-04 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
JP5947544B2 (ja) * 2008-08-29 2016-07-06 アスチュート メディカル,インコーポレイテッド 腎損傷および腎不全の診断および予後のための方法および組成物
EP3974836A1 (en) 2008-10-21 2022-03-30 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
AU2009308375B2 (en) * 2008-10-21 2015-06-25 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
BRPI0922021A2 (pt) 2008-11-10 2019-09-24 Astute Medical Inc método para avaliar a condição renal em um indivíduo, e, uso de um ou mais marcadores de lesão renal
CN104034901A (zh) * 2008-11-22 2014-09-10 阿斯图特医药公司 用于诊断和预后肾损伤和肾衰竭的方法和组合物
US9229010B2 (en) 2009-02-06 2016-01-05 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2010091231A1 (en) * 2009-02-06 2010-08-12 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
JP5819734B2 (ja) * 2009-02-12 2015-11-24 ストライカー コーポレイションStryker Corporation TGF−βスーパーファミリーメンバー含有タンパク質の最小に侵襲性の全身送達のための組成物および方法
SG173632A1 (en) * 2009-02-12 2011-09-29 Stryker Corp Peripheral administration of proteins including tgf-beta superfamily members for systemic treatment of disorders and disease
JP5749659B2 (ja) 2009-03-12 2015-07-15 ハーゼ インベストメンツ ウーゲー Bmpアンタゴニスト感受性が低下した骨形成タンパク質2(bmp2)変異体
WO2010144696A1 (en) 2009-06-11 2010-12-16 Burnham Institute For Medical Research Directed differentiation of stem cells
US8871459B2 (en) 2009-08-07 2014-10-28 Astute Medical, Inc. Method for evaluating renal status by determining beta-2-glycoprotein 1
US20110224410A1 (en) 2009-09-17 2011-09-15 Hile David Buffers for Controlling the pH of Bone Morphogenetic Proteins
EP2496942B1 (en) 2009-11-07 2017-03-22 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CN102725636B (zh) 2009-12-20 2015-04-01 阿斯图特医药公司 用于肾损伤和肾衰竭的诊断及预后的方法和组合物
AU2010341565A1 (en) 2009-12-22 2012-07-12 Stryker Corporation BMP-7 variants with reduced immunogenicity
NZ700695A (en) 2010-02-05 2016-05-27 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
JP5998057B2 (ja) 2010-02-26 2016-11-30 アスチュート メディカル,インコーポレイテッド 腎損傷および腎不全の診断と予後のための方法と組成物
WO2011162819A1 (en) 2010-06-23 2011-12-29 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
ES2667066T3 (es) 2010-05-24 2018-05-09 The Trustees Of Columbia University In The City Of New York Proteínas NGAL mutantes y usos de las mismas
WO2011162821A1 (en) 2010-06-23 2011-12-29 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CA2807343C (en) 2010-08-20 2018-05-22 Wyeth Llc Designer osteogenic proteins
US9688735B2 (en) 2010-08-20 2017-06-27 Wyeth Llc Designer osteogenic proteins
US10935548B2 (en) 2011-12-08 2021-03-02 Astute Medical, Inc. Methods for diagnosis and prognosis of renal injury and renal failure using insulin-like growth factor-binding protein 7 and metalloproteinase inhibitor 2
CA2886788C (en) 2012-10-08 2022-04-19 Relypsa, Inc. Potassium-binding agents for treating hypertension and hyperkalemia
EP2925337B1 (en) 2012-11-21 2019-07-03 The Trustees of Columbia University in the City of New York Mutant ngal proteins and uses thereof
ES2926197T3 (es) 2013-01-17 2022-10-24 Astute Medical Inc Métodos y composiciones para el diagnóstico y pronóstico de lesión renal e insuficiencia renal
US8956829B2 (en) 2013-01-25 2015-02-17 Warsaw Orthopedic, Inc. Human recombinant growth and differentiaton factor-5 (rhGDF-5)
US9051389B2 (en) 2013-01-25 2015-06-09 Warsaw Orthopedic, Inc. Expression conditions and methods of human recombinant growth and differentiation factor-5 (rhGDF-5)
US8945872B2 (en) 2013-01-25 2015-02-03 Warsaw Orthopedic, Inc. Methods of purifying human recombinant growth and differentiation factor-5 (rhGDF-5) protein
US9359417B2 (en) 2013-01-25 2016-06-07 Warsaw Orthopedic, Inc. Cell cultures and methods of human recombinant growth and differentiaton factor-5 (rhGDF-5)
US9169308B2 (en) 2013-01-25 2015-10-27 Warsaw Orthopedic, Inc. Methods and compositions of human recombinant growth and differentiation factor-5 (rhGDF-5) isolated from inclusion bodies
EP2784083A1 (en) 2013-03-28 2014-10-01 Charité - Universitätsmedizin Berlin Bone Morphogenetic Protein (BMP) variants with highly reduced antagonist sensitivity and enhanced specific biological activity
JP2016536588A (ja) * 2013-11-11 2016-11-24 ゼネラル・エレクトリック・カンパニイ ロータ速度の測定における誤差を低減する方法
EP2944326B1 (en) 2014-05-16 2018-11-21 Cyanagen Srl Tricarbocyanine-cyclodextrin-conjugates and their use for the diagnosis of kidney diseases
EP4406585A3 (en) 2015-02-13 2024-10-23 Factor Bioscience Inc. Nucleic acid products and methods of administration thereof
EP3465201A4 (en) 2016-06-06 2020-08-26 Astute Medical, Inc. MANAGEMENT OF ACUTE KIDNEY DAMAGE USING INSULINOMIMETIC GROWTH FACTOR BINDING PROTEIN 7 AND TISSUE METALLOPROTEINASE 2 INHIBITOR
IL308824A (en) 2016-08-17 2024-01-01 Factor Bioscience Inc Nucleic acid products and methods of administration thereof
JP2019039673A (ja) * 2017-08-22 2019-03-14 セイコーエプソン株式会社 時間デジタル変換回路、回路装置、物理量測定装置、電子機器及び移動体

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1156741B (it) * 1978-05-15 1987-02-04 Sigma Tau Ind Farmaceuti Applicazione terapeutica della carnitina e di alcuni derivati acilati della carnitina nell'emodialisi
US4342828A (en) 1979-07-20 1982-08-03 Morinaga Milk Industry Co., Ltd. Method for producing substance capable of stimulating differentiation and proliferation of human granulopoietic stem cells
US4627839A (en) * 1985-11-21 1986-12-09 American Hospital Supply Corporation Patient controlled analgesia conversion
US5013649A (en) 1986-07-01 1991-05-07 Genetics Institute, Inc. DNA sequences encoding osteoinductive products
IL83003A (en) 1986-07-01 1995-07-31 Genetics Inst Osteoinductive factors
US5266683A (en) 1988-04-08 1993-11-30 Stryker Corporation Osteogenic proteins
US5011691A (en) 1988-08-15 1991-04-30 Stryker Corporation Osteogenic devices
US5045452A (en) 1988-09-02 1991-09-03 Brigham And Women's Hospital Method for evaluating nephrotoxicity
DE69031939T2 (de) 1989-03-28 1998-09-10 Genetics Institute, Inc., Cambridge, Mass. Osteoinduktive zusammensetzungen
DK0536186T3 (da) 1990-05-16 2002-05-21 Genetics Inst Knogle- og brusk-dannelsesfremkaldende proteiner
JPH0426624A (ja) * 1990-05-18 1992-01-29 Tsumura & Co 慢性腎不全改善剤
EP0533840B1 (en) 1990-06-22 1996-12-11 E.I. Du Pont De Nemours And Company Treatment of chronic renal failure with imidazole angiotensin-ii receptor antagonists
CA2104678C (en) * 1991-03-11 2002-05-14 Charles M. Cohen Protein-induced morphogenesis
JP3627985B2 (ja) 1991-03-11 2005-03-09 キュリス インコーポレイテッド タンパク質により誘導される形態形成
US6077823A (en) * 1991-03-11 2000-06-20 Creative Biomolecules, Inc. Method for reducing tissue damage associated with ischemia-reperfusion or hypoxia injury
US5849686A (en) * 1991-03-11 1998-12-15 Creative Biomolecules, Inc. Morphogen-induced liver regeneration
US7056882B2 (en) * 1991-03-11 2006-06-06 Curis, Inc. Treatment to prevent loss of and/or increase bone mass in metabolic bone diseases
US6194376B1 (en) * 1991-03-11 2001-02-27 Creative Biomolecules, Inc. Method for modulating inflammatory response comprising administering morphogen
US6287816B1 (en) 1991-06-25 2001-09-11 Genetics Institute, Inc. BMP-9 compositions
EP0601129B1 (en) 1991-08-30 2000-11-15 Creative Biomolecules, Inc. Morphogenic protein screening method
ES2149776T5 (es) 1991-08-30 2004-07-01 Curis, Inc. Modulacion, inducida por un morfogeno, de la respuesta inflamatoria.
EP1637156A1 (en) 1991-08-30 2006-03-22 Curis, Inc. Systemic administration of osteogenic proteins in the treatment of metabolic bone diseases
US6120760A (en) * 1992-02-12 2000-09-19 Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Growth/differentiation factors of the TGF-β family
DK0653942T3 (da) 1992-07-31 2003-10-20 Curis Inc Morphogen-induceret nerve-regenerering og -reparation
EP0661933B1 (en) 1992-07-31 1998-04-22 Creative Biomolecules, Inc. Morphogen-enriched dietary composition
ATE287949T1 (de) 1992-07-31 2005-02-15 Stryker Corp Löslicher komplex morphogener proteine und zusammensetzungen davon
WO1994006449A2 (en) 1992-09-16 1994-03-31 Creative Biomolecules, Inc. Morphogen-induced liver regeneration
JPH08503198A (ja) 1992-11-03 1996-04-09 クリエイティブ バイオモレキュルズ,インコーポレイテッド Op−3誘導形態形成
US5372335A (en) 1992-12-18 1994-12-13 Scott H. Yenzer Aerial marker ball and method of placement
JPH08510446A (ja) 1993-03-04 1996-11-05 クリエイティブ バイオモレキュルズ,インコーポレイテッド 組換え骨形成タンパク質を生成するための方法および組成物
US5631159A (en) 1993-09-22 1997-05-20 Creative Biomolecules, Inc. Lipid-modified serum free media
US5585237A (en) 1993-10-25 1996-12-17 Creative Biomolecules, Inc. Methods and compositions for high protein production from recombinant DNA
ATE225666T1 (de) * 1993-11-15 2002-10-15 Celtrix Pharma Verwendung von igf-1 und igfbp-3 zur herstellung eines arzneimittels zur behandlung von einer nierenerkrankung
US5525621A (en) * 1994-05-20 1996-06-11 Cytos Pharmaceuticals Llc Imidazole derivatives as protective agents in reperfusion injury and severe inflammatory responses
US5714511A (en) 1995-07-31 1998-02-03 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Selective prevention of organ injury in sepsis and shock using selection release of nitric oxide in vulnerable organs
US5723411A (en) * 1995-10-31 1998-03-03 E. I. Du Pont De Nemours And Company Herbicidal pyridazinones
CN1181885C (zh) * 1996-03-22 2004-12-29 通用医疗公司 中枢神经系统局部缺血或损伤后多肽生长因子的给药
US5820589A (en) * 1996-04-30 1998-10-13 Medtronic, Inc. Implantable non-invasive rate-adjustable pump
US6498142B1 (en) * 1996-05-06 2002-12-24 Curis, Inc. Morphogen treatment for chronic renal failure
US5879908A (en) * 1997-04-30 1999-03-09 Smithkline Beecham Corporation CRFG-1a, a target and marker for chronic renal failure
US7147839B2 (en) * 1998-05-29 2006-12-12 Curis, Inc. Methods for evaluating tissue morphogenesis and activity

Similar Documents

Publication Publication Date Title
JP2000501599A5 (cg-RX-API-DMAC10.html)
JP2000501018A5 (cg-RX-API-DMAC10.html)
JP2000500076A5 (cg-RX-API-DMAC10.html)
JP2001504960A5 (cg-RX-API-DMAC10.html)
JP2000501324A5 (cg-RX-API-DMAC10.html)
JP2000510124A5 (cg-RX-API-DMAC10.html)
JP2000500055A5 (cg-RX-API-DMAC10.html)
JP2000516911A5 (cg-RX-API-DMAC10.html)
JP2001525689A5 (cg-RX-API-DMAC10.html)
JP2000500026A5 (cg-RX-API-DMAC10.html)
JP2000501338A5 (cg-RX-API-DMAC10.html)
JP2000500874A5 (cg-RX-API-DMAC10.html)
JP2000510510A5 (cg-RX-API-DMAC10.html)
JP2000516705A5 (cg-RX-API-DMAC10.html)
JP2001504437A5 (cg-RX-API-DMAC10.html)
JP2000502568A5 (cg-RX-API-DMAC10.html)
JP2000500912A5 (cg-RX-API-DMAC10.html)
JP2000502570A5 (cg-RX-API-DMAC10.html)
JP2001501883A5 (cg-RX-API-DMAC10.html)
JP2000501229A5 (cg-RX-API-DMAC10.html)
JP2000500857A5 (cg-RX-API-DMAC10.html)
JP2000502714A5 (cg-RX-API-DMAC10.html)
JP2000509972A5 (cg-RX-API-DMAC10.html)
JP2000509404A5 (cg-RX-API-DMAC10.html)
JP2001503914A5 (cg-RX-API-DMAC10.html)